Form 4: Perrigo Director Kevin Egan Granted 7,305 Restricted Stock Units

Perrigo Company plc Director Kevin Francis Egan has been granted 7,305 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Kevin Francis Egan, a Director of Perrigo Company plc (PRGO), was granted 7,305 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 14, 2025.
• Each RSU represents a contingent right to receive one Perrigo Company plc ordinary share.
• The RSUs are scheduled to vest on May 14, 2026.
• Following this transaction, Mr. Egan beneficially owns 7,305 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as the RSU grant aligns the director's interests with shareholders, which is generally viewed favorably. It's a standard compensation event, not indicative of extraordinary positive or negative news.

Positives

• The grant of Restricted Stock Units to Director Kevin Egan aligns his long-term interests with those of the company's shareholders, as the value of the RSUs is tied to the company's share price performance.
• Equity-based compensation is a common and effective method to incentivize directors and executives to contribute to the company's sustained growth and profitability.

Future Outlook

The granted Restricted Stock Units are set to vest on May 14, 2026, indicating a future conversion of these contingent rights into ordinary shares of Perrigo Company plc, subject to continued service.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a standard practice across various industries, including the pharmaceutical and consumer healthcare sectors where Perrigo operates. This form of equity compensation is widely used to attract, retain, and motivate key personnel by linking their compensation directly to the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a common and widely accepted form of executive and director compensation in publicly traded companies, including peers in the healthcare and consumer goods sectors such as Johnson & Johnson, Procter & Gamble, and Pfizer, which frequently utilize equity awards to align management and board interests with shareholders.
• The vesting schedule, typically over one to several years, is also standard, ensuring long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Kevin Francis Egan, a Director of Perrigo Company plc, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance and increased shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing, though it reflects the company's overall compensation philosophy for leadership.

Next Steps

• The 7,305 Restricted Stock Units granted to Kevin Egan are expected to vest on May 14, 2026, at which point they will convert into ordinary shares of Perrigo Company plc.

Key Dates

Recommendation

Keywords

Perrigo Company plc, PRGO, SEC Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Corporate Governance